At the same time, it has been found that Keap1 mutations lead to impairment of the Nrf2-Keap1-ARE signaling pathway, affecting its binding to Nrf2, causing a large accumulation of Nrf2, and increasing the resistance of tumor cells. The gene discussed is NFE2L2; the disease is neoplasm.